Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2012. The report details a specific corporate action regarding the company's share buyback program authorized by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on share repurchase activity and capital structure.
- Shares Purchased: 1,500,000 Ordinary Shares of 25 pence each.
- Purchase Date: July 27, 2012.
- Price Range: Highest price paid was 1,450.5 pence per share; lowest price paid was 1,420 pence per share.
- Treasury Holdings (Settled): 478,307,927 shares (8.75% of total issued share capital).
- Treasury Holdings (Including Unsettled): 481,407,927 shares (9.65% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,991,152,839 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1.5 million shares for Treasury. Consequently, the percentage of shares held in Treasury increased to 9.65% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (4,991,152,839) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (481,407,927) to assess the impact on total voting rights.
- Review the price paid (1,420 to 1,450.5 pence) against market prices on July 27, 2012.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial statements.